From Morningstar: "We believe Big Pharma firms will probably continue to rummage around biotechnology for their next targets, and our top five biotech takeout targets all offer the combination of highly sought factors: pipeline potential, therapeutic area attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx (ONXX), Regeneron (REGN), Incyte (INCY), Biomarin (BMRN), and Seattle Genetics (SGEN)."
1. At what takeout price?
2. Only IMGN will be left as a major ADC play. How high will IMGN pps soar? Do you SGEN longs have positions in IMGN?